185 related articles for article (PubMed ID: 27793187)
1. A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS.
Pang X; Liu M
Chin J Cancer; 2016 Oct; 35(1):92. PubMed ID: 27793187
[TBL] [Abstract][Full Text] [Related]
2. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.
Wang J; Hu K; Guo J; Cheng F; Lv J; Jiang W; Lu W; Liu J; Pang X; Liu M
Nat Commun; 2016 May; 7():11363. PubMed ID: 27193833
[TBL] [Abstract][Full Text] [Related]
3. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer.
Yang Z; Liang SQ; Saliakoura M; Yang H; Vassella E; Konstantinidou G; Tschan M; Hegedüs B; Zhao L; Gao Y; Xu D; Deng H; Marti TM; Kocher GJ; Wang W; Schmid RA; Peng RW
EMBO Mol Med; 2021 Sep; 13(9):e13193. PubMed ID: 34369083
[TBL] [Abstract][Full Text] [Related]
5. Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS.
Narvaez AJ; Ber S; Crooks A; Emery A; Hardwick B; Guarino Almeida E; Huggins DJ; Perera D; Roberts-Thomson M; Azzarelli R; Hood FE; Prior IA; Walker DW; Boyce R; Boyle RG; Barker SP; Torrance CJ; McKenzie GJ; Venkitaraman AR
Cell Chem Biol; 2017 Aug; 24(8):1017-1028.e7. PubMed ID: 28807782
[TBL] [Abstract][Full Text] [Related]
6. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
Kreis NN; Louwen F; Zimmer B; Yuan J
Oncotarget; 2015 Mar; 6(9):6611-26. PubMed ID: 25483104
[TBL] [Abstract][Full Text] [Related]
7. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
Lin YC; Sun SH; Wang FF
Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
[TBL] [Abstract][Full Text] [Related]
8. A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.
Dietlein F; Kalb B; Jokic M; Noll EM; Strong A; Tharun L; Ozretić L; Künstlinger H; Kambartel K; Randerath WJ; Jüngst C; Schmitt A; Torgovnick A; Richters A; Rauh D; Siedek F; Persigehl T; Mauch C; Bartkova J; Bradley A; Sprick MR; Trumpp A; Rad R; Saur D; Bartek J; Wolf J; Büttner R; Thomas RK; Reinhardt HC
Cell; 2015 Jul; 162(1):146-59. PubMed ID: 26140595
[TBL] [Abstract][Full Text] [Related]
9. Defeat mutant KRAS with synthetic lethality.
Pang X; Liu M
Small GTPases; 2017 Oct; 8(4):212-219. PubMed ID: 27463838
[TBL] [Abstract][Full Text] [Related]
10. Synergy of WEE1 and mTOR Inhibition in Mutant
Hai J; Liu S; Bufe L; Do K; Chen T; Wang X; Ng C; Li S; Tsao MS; Shapiro GI; Wong KK
Clin Cancer Res; 2017 Nov; 23(22):6993-7005. PubMed ID: 28821559
[No Abstract] [Full Text] [Related]
11. Combined treatment of ABT199 and irinotecan suppresses KRAS-mutant lung cancer cells.
Xu Y; Zong S; Gao X; Zhang H; Wang B; Li P; Liu T; Li S
Gene; 2019 Mar; 688():1-6. PubMed ID: 30415007
[TBL] [Abstract][Full Text] [Related]
12. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
13. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma.
Hu K; Li K; Lv J; Feng J; Chen J; Wu H; Cheng F; Jiang W; Wang J; Pei H; Chiao PJ; Cai Z; Chen Y; Liu M; Pang X
J Clin Invest; 2020 Apr; 130(4):1752-1766. PubMed ID: 31874110
[TBL] [Abstract][Full Text] [Related]
14. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL
Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230
[TBL] [Abstract][Full Text] [Related]
15. Synergistic Antitumor Effect of Taxanes and CDK4/6 Inhibitor in Lung Cancer Cells and Mice Harboring KRAS Mutations.
Son KH; Kim MY; Shin JY; Kim JO; Kang JH
Anticancer Res; 2021 Oct; 41(10):4807-4820. PubMed ID: 34593430
[TBL] [Abstract][Full Text] [Related]
16. Lung-cancer chemoprevention by induction of synthetic lethality in mutant KRAS premalignant cells in vitro and in vivo.
Huang S; Ren X; Wang L; Zhang L; Wu X
Cancer Prev Res (Phila); 2011 May; 4(5):666-73. PubMed ID: 21543344
[TBL] [Abstract][Full Text] [Related]
17. Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
Umelo IA; De Wever O; Kronenberger P; Van Deun J; Noor A; Singh K; Teugels E; Chen G; Bracke M; De Grève J
Oncotarget; 2015 Aug; 6(24):20132-44. PubMed ID: 25992771
[TBL] [Abstract][Full Text] [Related]
18. Blocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer.
Feng J; Jiang W; Liu Y; Huang W; Hu K; Li K; Chen J; Ma C; Sun Z; Pang X
Biochem Pharmacol; 2020 Jul; 177():113960. PubMed ID: 32298693
[TBL] [Abstract][Full Text] [Related]
19. STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway.
Wang Z; Yin M; Chu P; Lou M
Aging (Albany NY); 2019 Sep; 11(17):7187-7196. PubMed ID: 31484165
[TBL] [Abstract][Full Text] [Related]
20. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
